mimmunМедицинская иммунологияMedical Immunology (Russia)1563-06252313-741XSPb RAACI10.15789/1563-0625-IOS-2486mimmun-2486Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESВлияние мутационных вариантов спайкового гликопротеина и РНК-зависимой РНКполимеразы (nsp12) SARS-CoV-2 на участки стыковки с ремдесивиромInfluence of SARS-CoV-2 variants’ spike glycoprotein and RNA-dependent RNA polymerase (nsp12) mutations on remdesivir docking residueshttps://orcid.org/0000-0001-8988-5957ДавудАли А.DawoodAli A.

Автор: Али А. Давуд – кандидат микробиологических наук, лектор, кафедра анатомии.

1, г. Мосул. Тел.: 00964 (770)-176-8002

PhD (Microbiology), Lector, Department of Anatomy, College of Medicine.

st. 1, Mosul, Phone: 00964 (770)-176-8002

aad@uomosul.edu.iqМедицинский колледж, Мосульский университетИракUniversity of MosulIraq202213072022243617628Copyright © Давуд А.А., 20222022Давуд А.А.Dawood A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.mimmun.ru/mimmun/article/view/2486

В связи с быстрым развитием и эволюцией новых вариантов SARS-CoV-2 возникли проблемы, касающиеся их потенциального влияния на эффективность существующих вакцин. При этом наиболее значимые мутации касаются гена спайкового гликопротеина вируса. Ремдесивир, ингибирующий активность РНК-зависимой РНК-полимеразы (РдРп), является единственным препаратом, принятым FDA для лечения COVID-19 (nsp12). Исследовалось связывание (стыковка) гибкого лиганда (ремдесивира) с жесткими рецепторами (спайковый белок и РдРп). В ряде работ было обнаружено, что мутации спайкового гликопротеина и РдРп оказывают существенное влияние на поведение вируса и, в конечном счете, – на состояние здоровья человека. Показано, что позиция стыковки ремдесивира со спайковым белком и РдРп не определяется мутациями в недостающих петлях. Ремдесивир может связываться только с В- и С-цепями спайкового белка. Некоторые мутации могут передаваться в отдельных вариантах без изменения типа аминокислот, как, например, K417N, L452R, N501Y, D614G, T716I и S982A.

Rapid emergence and evolution of novel SARS-CoV-2 variants has raised concerns about their potential impact on efficiency of currently available vaccines. Among the most significant target mutations in the virus are those of the spike glycoprotein. Remdesivir, which inhibits the polymerase activity of the RNAdependent RNA polymerase RdRp, is the only medicine approved by FDA for treatment of COVID-19 (nsp12). The docking features of the flexible ligand (remdesivir) with the stiff receptors was investigated in the present study (S protein and RdRp interaction). In various studies, the spike glycoprotein and RdRp mutations were found to have a significant influence upon viral behaviour and, as a result, affect human health. The docking position of remdesivir with the S and RdRp proteins was shown to be unaffected by mutations in the missing loops. The remdesivir can only bind the B and C chains of S protein. Some mutations can be transferred between variations, without changing the type of amino acid, such as K417N, L452R, N501Y, D614G, T716I, and S982A.

COVID-19ремдесивирРНК-зависимая РНК-полимеразаспайковый белокмутацииCOVID-19remdesivirRdRpS proteinmutationReferencesBaum A., Fulton B.O., Wloga E., Copin R., Pascal K.E., Russo V., Giordano S., Lanza K., Negron N., Ni M., Wei Y., Atwal G.S., Murphy A.J., Stahl N., Yancopoulos G.D., Kyratsous C.A. Antibody cocktail to SARSCoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science, 2020, Vol. 369, pp. 1014-1018.Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382: 727–733. doi.org/10.1056/NEJMoa2001017.Choy K.-T., Wong A.Y.-L., Kaewpreedee P., Sia S.F., Chen D., Hui K.P.Y., Chu D.K.W., Chan M.C.W., Cheung P.P.-H., Huang X., Peiris M., Yen H.-L. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARSCoV-2 replication in vitro. Antiviral Res., 2020, Vol. 178, 104786. doi: 10.1016/j.antiviral.2020.104786.Salleh MZ, Derrick JP, Deris ZZ. Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. Inter J Mole Sci. 2021; 22(14):7425. doi.org/10.3390/ijms22147425.Dawood A., Altobje M., Alnori H. Compatibility of the ligand binding sites in the spike glycoprotein of covid-19 with those in the aminopeptidase and the caveolins 1, 2 proteins. Res. J. Pharm. Tech., 2021, Vol. 14, no. 9, pp. 4760-4766.Wu C, Chen X, Cai Y, Xia J, Zhou X. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2019.Dawood A., Altobje M., Alrassam Z. Molecular docking of SARS-CoV-2 nucleocapsid protein with angiotensin-converting enzyme II. Mikrobiol. Zhu, 2021, Vol. 83, no. 2, pp. 82-92.Shaeen A, Sattar N, Ibrahim M, and Irfan M. Role of Remdesivir in COVID-19. Aus J Pulm Res Med. 2021; 8(1):1071.Dawood A., Altobje M. Inhibition of N-linked glycosylation by nunicamycin may contribute to the treatment of SARS-CoV-2. Microbiol. Path., 2020, Vol. 149, 104586. doi: 10.1016/j.micpath.2020.104586.Shehroz M, Zaheer T, and Hussain T. Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment. Heliyon. 2020; e05278. doi.org/10.1016/j.heliyon.2020.e05278.Dawood A. Glycosylation, ligand binding sites and antigenic variations between membrane glycoprotein of COVID-19 and related coronaviruses. Vacunas. 2021, Vol. 22, no. 1, pp. 1-9.Dawood A, Altobje M, and Alnori H. Compatibility of the Ligand Binding Sites in the Spike Glycoprotein of COVID-19 with those in the Aminopeptidase and the Caveolins 1, 2 Proteins. Res J Pharm Tech. 2021; 14(9): 4760-4766. Doi.org/10.52711/0974-360X.2021.00828.Dawood A. Identification of CTL and B-cell epitopes in the Nucleocapsid Phosphoprotein of COVID-19 using Immunoinformatics. Microbiol. J., 2021, Vol. 83, no. 1, pp. 78-86.Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020; 369, 1014–1018.Dawood A. New variant of SARS-CoV-2 in South Africa. Prog. Med. Sc., 2021, Vol. 5, no. 1, pp. 1-2.Senger MR, Evangelista TCS, Dantas RF, Santana MVDS, Gonçalves LCS, de Souza Neto LR, et al. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. Mem Inst Oswaldo Cruz. 2020; Oct 2; 115:e200254. doi: 10.1590/0074-02760200254. PMID: 33027420; PMCID: PMC7534958.Dawood A. Using remdesivir and dexamethasone for treatment of SARS-CoV-2 shortens the patient’s stay in the hospital. Asi an J. Pharm. Res., 2021, Vol. 11, Iss. 2, 138-0. doi: 10.52711/2231-5691.2021.00026.Wang M, Cao R, Zhang L, Yang X, Liu J. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30: 269-271.Deshpande R., Tiwari P., Nyayanit N., Modak M. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2. Eur. J. Pharmacol., 2020, Vol. 886, 173430. doi.org/10.1016/j.ejphar.2020.173430.Hall Jr, and Ji H-F. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020; 35:101646. doi .org/0.1016/j.tmaid.2020.101646.Eskier D., Karakülah G., Suner A., Oktay Y. RdRp mutations are associated with SARS-CoV-2 genome evolution. Peer J., 2020, Vol. 8, e9587. doi:/10.7717/peerj.9587.Choy T, Wong Y, Kaewpreedee P, Sia F, Chen D, Hui Y, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARSCoV-2 replication in vitro. Antiviral Res. 2020; 178:104786. Doi.org/10.1016/j.antiviral.2020.104786.Eweas A., Alhossary A., Abdul-Moneim A. Molecular Docking Reveals ivermectin and remdesivir as potential repurposed drugs against SARS-CoV-2. Front. Microbiol., 2021, Vol. 11, e592908. doi: 10.3389/fmicb.2020.592908.Grein J, Ohmagari N, Shin D, Diaz G, Asperges E. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020; 382: 2327-2336.Garvin M.R., Prates E.T., Pavicic M., Jones P., Amos B.K., Geiger A., Shah M.B., Streich J., Gazolla J.G.F.M., Kainer D., Cliff A., Romero J., Keith N., Brown J.B., Jacobson D. Potentially adaptive SARS-CoV-2 mutations discovered with novel spatiotemporal and explainable AI models. Genome Biol., 2020, Vol. 21, 304. doi: 10.1186/s13059-020-02191-0.Dawood A. Using Remdesivir and Dexamethasone for Treatment of SARS-CoV-2 Shortens the patient's stay in the Hospital. Asi J Pharm Res. 2021; 11(2):138-0. doi.org/10.52711/2231-5691.2021.00026.Grein J., Ohmagari N., Shin D., Diaz G., Asperges E. Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med., 2020, Vol. 382, pp. 2327-2336.Yin W, Mao C, Luan X, Shen D-D, Shen Q, Su H., et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science.2020; 368: 1499–1504. doi.org/10.1126/science.abc1560.Hall Jr., Ji H-F. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med. Infect. Dis., 2020, Vol. 35, 101646. doi: 0.1016/j.tmaid.2020.101646.Eweas A, Alhossary A, and Abdul-Moneim A. Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs against SARS-CoV-2. Front Micro. 2021; 11:e 592908. doi.org/10.3389/fmicb.2020.592908.Henderson R., Edwards R.J., Mansouri K., Janowska K., Stalls V., Gobeil S.M.C., Kopp M., Li D., Parks R., Hsu A.L., Borgnia M.J., Haynes B.F., Priyamvada acharya controlling the SARS-CoV-2 spike glycoprotein conformation. Nat. Struct. Mol. Biol., 2020, Vol. 27, pp. 925-933.Sada, M. et al. Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico. Microorganisms.2020: 8, 1610.Ilmjärv S., Abdul F., Acosta-Gutiérrez S., Estarellas C., Galdadas I., Casimir M., Alessandrini M., Gervasio F.L., Krause K.-H. Concurrent mutations in RNA-dependent RNA polymerase and spike protein emerged as the epidemiologically most successful SARS-CoV-2 variant. Sci. Rep., 2021, Vol. 11, 13705. doi: 10.1038/s41598021-91662-w.Hall Jr, and Ji H.-F. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020; 35:101646. Doi.org/10.1016/j.tmaid.2020.101646.Jean S., Lee I., Hsueh R. Treatment options for COVID-19: the reality and challenges. J. Microbiol. Immunol. Infect., 2020, Vol. 53, pp. 436-443.Dawood A, Altobje M, and Alrassam Z. Molecular Docking of SARS-CoV-2 Nucleocapsid Protein with Angiotensin-Converting Enzyme II. Mikrobio Zhu. 2021; 83(2):82-92. Doi.org/10.15407/microbiolj83.02.082.Kumar Y., Singh H., Patel C.N. In silico prediction of potential inhibitors for the main protease of SARSCoV-2 using molecular docking and dynamics simulation based drug-repurposing. J. Infect. Public Health, 2020, Vol. 13, pp. 1210-1223.Sun C, Zhang J, Wei J, Zheng X, Zhao X, and Fang Z, et al. Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein. PLOS One. 2021; Jan: 1-21. doi.org/10.1371/journal.pone.0245975.Mari A., Roloff T., Stange M., Søgaard K.K., Asllanaj E., Tauriello G., Alexander L.T., Schweitzer M., Leuzinger K., Gensch A., Martinez A.E., Bielicki J., Pargger H., Siegemund M., Nickel C.H., Bingisser R., Osthoff M., Bassetti S., Sendi P., Battegay M., Marzolini C., Seth-Smith H.M.B., Schwede T., Hirsch H.H., Egli A. Global genomic analysis of SARS-CoV-2 RNA dependent RNA polymerase evolution and antiviral drug resistance. Microorganisms, 2021, Vol. 9, no. 5, 1094. doi: 10.3390/microorganisms9051094.Zhang, Q., Xiang, R., Huo, S. et al. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Sig Transduct Target Ther. 2021; 6(233) doi.org/10.1038/s41392-021-00653-w.Nguyen H., Thai N., Truong D., Li M. Remdesivir Strongly Binds to Both RNA-Dependent RNA polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations. J. Phys. Chem., 2020, Vol. 124, pp. 11337-11348.Dawood A. Glycosylation, ligand binding sites and antigenic variations between membrane glycoprotein of COVID-19 and related coronaviruses. Vacunas. 2021; 22(1): 1-9. Doi.org/10.1016/j.vacun.2020.09.005.Pachetti M., Marini B., Benedetti F., Giudici F., Mauro E., Storici P., Masciovecchio C., Angeletti S., Ciccozzi M., Gallo R.C., Zella D., Ippodrino R. Emerging SARS-CoV-2 mutation hot spots include a novel RNAdependent-RNA polymerase variant. J. Transl. Med., 2020, Vol. 18, no. 1, 179. doi.org/10.1186/s12967-020-02344-6.Dawood A. New Variant of SARS-CoV-2 in South Africa. Prog Med Sc. 2021; 5(1): 1-2. doi.org/10.5455/pms.20211013.Sada M., Saraya T., Ishii H., Okayama K., Hayashi Y., Tsugawa T., Nishina A., Murakami K., Kuroda M., Ryo A., Kimura H. Detailed molecular interactions of favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza virus polymerases in silico. Microorganisms, 2020, Vol. 8, no. 10, 1610. doi: 10.3390/microorganisms8101610.Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30:269–271. doi.org/10.1038/s41422-020-0282-0.Salleh M.Z., Derrick J.P., Deris Z.Z. Structural evaluation of the spike glycoprotein variants on SARS-CoV-2 transmission and immune evasion. Inter. J. Mol. Sci., 2021, Vol. 22, no. 14, 7425. doi.org/10.3390/ijms22147425.Showers W, Leach S, Kechris K, and Strong M. Analysis of SARS-CoV-2 Mutations over Time Reveals Increasing Prevalence of Variants in the Spike Protein and RNA-Dependent RNA polymerase. bioRxiv. 2021. doi:/10.1101/2021.03.05.433666.Senger M.R., Evangelista T.C.S., Dantas R.F., Santana M.V.D.S., Gonçalves L.C.S., de Souza Neto L.R., Ferreira S.B., Silva-Junior F.P. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. Mem. Inst. Oswaldo Cruz, 2020, Vol. 115, e200254. doi: 10.1590/0074-02760200254.Garvin R, Prates E, Pavicic M, et al. Potentially adaptive SARS-CoV-2 mutations discovered with novel spatiotemporal and explainable AI models. Genome Biol. 2020; 21 (304). doi.org/10.1186/s13059-020-02191-0.Shaeen A., Sattar N., Ibrahim M., Irfan M. Role of Remdesivir in COVID-19. Aus. J. Pulm. Res. Med., 2021, Vol. 8, no. 1, 1071.Dawood A. Identification of CTL and B-cell epitopes in the Nucleocapsid Phosphoprotein of COVID-19 using Immunoinformatics. Microbiol J. 2021; 83(1): 78-86. doi.org/10.15407/microbiolj83.01.078.Sheahan T.P., Sims A.C., Leist S.R., Schafer A., Won J. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun., 2020, Vol. 11, no. 1, 222. doi: 10.1038/s41467-019-13940-6.Mari A, Roloff T, Stange M, Søgaard K, Asllanaj E, Tauriello G, et al. Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance. Microorganisms. 2021; 9(5):1094. doi.org/10.3390/microorganisms9051094.Shehroz M., Zaheer T., Hussain T. Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment. Heliyon, 2020, Vol. 6, no. 10, e05278. doi.org/10.1016/j.heliyon.2020.e05278.Dawood A, Altobje M. Inhibition of N-linked Glycosylation by Tunicamycin May Contribute to The Treatment of SARS-CoV-2. Microbiol Path. 2020; 149:104586. doi.org/10.1016/j.micpath.2020.104586.Showers W., Leach S., Kechris K., Strong M. Analysis of SARS-CoV-2 Mutations over time reveals increasing prevalence of variants in the spike protein and RNA-dependent RNA polymerase. bioRxiv, 2021. doi: 10.1101/2021.03.05.433666.Nguyen H, Thai N, Truong D, and Li M. Remdesivir Strongly Binds to Both RNA-Dependent RNA polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations. J Phys Chem. 2020; 124, 11337−11348. doi.org/10.1021/acs.jpcb.0c07312.Sun C., Zhang J., Wei J., Zheng X., Zhao X., Fang Z., Xu D., Yuan H., Liu Y. Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein. PLoS One, 2021, Vol. 16, no. 1, e0245975. doi: 10.1371/journal.pone.0245975.Kumar, Y., Singh, H., and Patel, C. N. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. J Infect Pub Heal. 2020; 13: 1210–1223. doi.org/10.1016/j.jiph.2020.06.016.Walls C., Park Y.-J., Tortorici A., Wall A., Mcguire T., Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 2020, Vol. 181, pp. 281.e6-292.e6.Williamson B, Feldmann F, Schwarz B, Meade-White K, Porter D. Clinical benefit of remdesivir in rhesus macaques infected with COVID-19. 2020.Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2020, Vol. 30, pp. 269-271.Sheahan TP, Sims AC, Leist SR, Schafer A, Won J. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020; 11: 222.Williamson B.N., Feldmann F., Schwarz B., Meade-White K., Porter D.P., Schulz J., van Doremalen N., Leighton I., Yinda C.K., Pérez-Pérez L., Okumura A., Lovaglio J., Hanley P.W., Saturday G., Bosio C.M., Anzick S., Barbian K., Cihlar T., Martens C., Scott D.P., Munster V.J., de Wit E. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-19. Nature, 2020, Vol. 585, pp. 273-276.Yin, W. et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020; 368, 1499–1504.Wu A., Peng Y., Huang B., Ding X., Wang X., Niu P., Meng J., Zhu Z., Zhang Z., Wang J., Sheng J., Quan L., Xia Z., Tan W., Cheng G., Jiang T. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe, 2020, Vol. 27, pp. 325-328.Yurkovetskiy, L. et al. Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. Cell. 2020; 183: 739-751.e8.Wu C., Chen X., Cai Y., Xia J., Zhou X. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med., 2020, Vol. 180, no. 7, pp. 1-11.Sheahan P, Sims C, Leist R, Schäfer A, Won J, Brown J, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 2020; 11:222. doi.org/ 10.1038/s41467-019-13940-6.Yin W., Mao C., Luan X., Shen D.-D., Shen Q., Su H., Wang X., Zhou F., Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.-W., Tao S.-C., Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science, 2020, Vol. 368, pp. 1499-1504.Pachetti M, Marini B, Benedetti F. et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med. 2020; 18 (179). doi.org/10.1186/s12967-020-02344-6.Yurkovetskiy L. Wang X., Pascal K.E., Tomkins-Tinch C., Nyalile T.P., Wang Y., Baum A., Diehl W.E., Dauphin A., Carbone C., Veinotte K., Egri S.B., Schaffner S.F., Lemieux J.E., Munro J.B., Rafique A., Barve A., Sabeti P.C., Kyratsous C.A., Dudkina N.V., Shen K., Luban J. Structural and functional analysis of the D614G SARSCoV-2 spike protein variant. Cell, 2020, Vol. 183, pp. 739-751.e8.Walls C, Park Y.-J, Tortorici A, Wall A, Mcguire T, and Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020; 181: 281.e6–292.e6. doi.org/10.1016/j.cell.2020.11.032.Zhang Q., Xiang R., Huo S., Zhou Y., Jiang S., Wang Q., Yu F. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Sig. Transduct. Target. Ther., 2021, Vol. 6, no. 1, 233. doi: 10.1038/s41392-021-00653-w.Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020; 27, 325–328.Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D., Xu W., Wu G., Gao G.F., Tan W. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med., 2020, Vol. 382, pp. 727-733.Ilmjärv S, Abdul F, Acosta-Gutiérrez S. et al. Concurrent mutations in RNA-dependent RNA polymerase and spike protein emerged as the epidemiologically most successful SARS-CoV-2 variant. Sci Rep. 2021; 11 (13705). doi.org/10.1038/s41598-021-91662-w.Eskier D, Karakülah G, Suner A, Oktay Y. RdRp mutations are associated with SARS-CoV-2 genome evolution. Peer J. 2020; Jul 21; 8:e9587. doi:/10.7717/peerj.9587. PMID: 32742818. PMCID: PMC7380272.Eskier D, Karakülah G, Suner A, Oktay Y. RdRp mutations are associated with SARS-CoV-2 genome evolution. Peer J. 2020; Jul 21; 8:e9587. doi:/10.7717/peerj.9587. PMID: 32742818. PMCID: PMC7380272.Deshpande R, Tiwari P, Nyayanit N, and Modak M. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2. Eur J Pharmacol. 2020; 886:173430. doi.org/10.1016/j.ejphar.2020.173430.Deshpande R, Tiwari P, Nyayanit N, and Modak M. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2. Eur J Pharmacol. 2020; 886:173430. doi.org/10.1016/j.ejphar.2020.173430.Jean S, Lee I, and Hsueh R. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020; 53: 436–443.Jean S, Lee I, and Hsueh R. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020; 53: 436–443.Henderson R. et al. Controlling the SARS-CoV-2 spike glycoprotein conformation. Nat Struct Mol Biol. 2020; 27: 925–933.Henderson R. et al. Controlling the SARS-CoV-2 spike glycoprotein conformation. Nat Struct Mol Biol. 2020; 27: 925–933.

The authors declare that there are no conflicts of interest present.